葵花药业收警示函,达嘉维康副总经理辞职,长春高新1类新药获批临床,贝达药业与晟斯生物达成战略合作

谈医说药
Nov 02

贝达药业:为进一步拓展新药创新技术平台,丰富产品管线布局,公司与江苏晟斯生物制药有限公司、杭州晟斯生物制药有限公司达成战略合作,贝达药业将在研发、临床、生产、注册及销售推广等环节支持晟斯生物,推动相关产品的研发和商业化。公司全资子公司浙江贝达医药销售有限公司与杭州晟斯生物签署《商业合作协议》,获授FRSW117产品在大中华区域的独家经销权。目标产品FRSW117属于治疗用生物制品1类,拟用于血友病...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10